Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2023-12-15
2024-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
APRVplus
An Early Pathophysiology-driven Airway Pressure Release Ventilation
APRVplus
Early Pathophysiology-driven Airway Pressure Release Ventilation (APRVplus)
TCAV
Time Controlled Adaptive Ventilation (TCAV)
TCAV
Time-Controlled Adaptive Ventilation (TCAV)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
APRVplus
Early Pathophysiology-driven Airway Pressure Release Ventilation (APRVplus)
TCAV
Time-Controlled Adaptive Ventilation (TCAV)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* meet the 2023 global new definition of ARDS
Exclusion Criteria
* The expected duration of mechanical ventilation was less than 48 hours
* Intracranial hypertension (suspected or confirmed)
* Neuromuscular disorders that are known to prolong the need for mechanical ventilation
* Known or suspected chronic obstructive pulmonary disease(COPD)
* Terminal stage of disease
* Pneumothorax (drained or not)at enrollment
* Treatment with extracorporeal support (ECMO) at enrollment
* There was a lack of commitment to life support
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhou Yongfang
Zhou Yongfang
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023 approved No.193
Identifier Type: -
Identifier Source: org_study_id